Roham Foroumadi

MD| PGY-1 Resident @MayoSurgery | Previous Postdoctoral Research Fellow @CleClinicMD| Sports Enthusiast 🏃| Pianist🎼

[Roham Foroumadi @RForoumadi]

This is surreal! A dream came true!
I matched in Preliminary General Surgery Residency @MayoSurgery. My sincere gratitude should go to Prof. @Ali_Aminian_MD for his unwavering support. i am sincerely grateful to @marielariveram for this opportunity! #Match2025 @TheNRMP

[Mayo Clinic General Surgery Residency @MayoSurgery]

We are excited to welcome our next incoming general surgery residents! Welcome to the Mayo family! #gensurgmatch2025 #mayo #youlooklikeasurgeon #leftglovefirst

[Roham Foroumadi @RForoumadi]

Proud to have contributed to a project tackling one of the biggest questions in the field of obesity. Grateful for the opportunity to work alongside such an incredible team at Cleveland Clinic. Thank you, @Ali_Aminian_MD , for giving me the chance to be part of this milestone.

[Ali Aminian @Ali_Aminian_MD]

Today at @ClevelandClinic, we celebrated a major milestone: completion of enrollment for our randomized clinical trial comparing #BariatricSurgery, #Semaglutide, and #Tirzepatide.

Proud and grateful to work with an incredible team advancing the future of #obesity care & science.

[TCTMD @TCTMD]

Metabolic bariatric surgery may have better outcomes and lower costs over GLP-1s for people with type-2 diabetes and obesity. “Even in the GLP-1 era, surgery can still provide some additional benefit, including a reduction in mortality,” says @Ali_Aminian_MD. https://t.co/jvqi27dP8O

[Ted Kyle @ConscienHealth]

A new study today in @NatureMedicine tells us that long-term outcomes with #MetabolicSurgery are better than #GLP1 medicines alone for diabetes and obesity.
HT: @Ali_Aminian_MD @HamletGasoyan @DrButsch
https://t.co/kLVFD2IVFm

[Sobia Laique MD @SNLaiqueMD]

Excited to join Butts and Guts @ClevelandClinic to discuss the evolving #MASLD landscape—formerly known as fatty liver disease. We dive into updated nomenclature, diagnostic pathways, and emerging therapeutics shaping the future of care!

[Sobia Laique MD @SNLaiqueMD]

A first for #MASLD: The @CleClinicMD MASLD Task Force brings together experts in #endocrinology, #metabolicsurgery, and #transplant to tackle MASH across the full disease spectrum.
💊 Emerging therapeutics
📍 Challenging cases
🧠 Expert panel debate
Don’t miss this powerhouse event!

[Cleveland Clinic MD @CleClinicMD]

New findings suggest that bariatric surgery can effectively alleviate or improve symptoms related to idiopathic intracranial hypertension: https://t.co/3SYiUP8dLj

[Rita Rys @RitaRys1]

🚨 Not to Miss Free CME Event! 🚨 June 11 – LIVE from Cleveland Clinic: MASLD - NEW THERAPEUTIC OPPS. Join @SNLaiqueMD @MichelleKimMD @Ali_Aminian_MD @CleClinicMD, Keren Zhou, Yael Mauer, Mazhar Khalil for this CME MOC virtual event. Register now: https://t.co/AHuvNuXN0i

[Ali Aminian @Ali_Aminian_MD]

18 months after gastric bypass bariatric surgery:

✴️ BMI from 71 to 40

✴️ Weight from 456 lbs to 255 lbs

[IFSO @IfsoSecretariat]

Why is weight loss surgery called metabolic surgery?
@JaimePonceMD explains it all!

✔️ It regulates hunger and satiety hormones
✔️ Improves blood sugar control
✔️ Reduces risk factors for type 2 diabetes and other metabolic diseases

#IFSO #BariatricSurgery #MetabolicSurgery

[Roham Foroumadi @RForoumadi]

@CorcellesMd Thank you so much dear Dr. Corcelles! I really appreciate your support🙏

[Ali Aminian @Ali_Aminian_MD]

So proud of you!
You’ve worked incredibly hard past year, and it’s been such a joy to watch you grow.
Running a marathon after overcoming obesity is no small feat.
As your mentor, I couldn’t be prouder.
Wishing you all the success and joy as you start next chapter at @MayoClinic

[Roham Foroumadi @RForoumadi]

@Ali_Aminian_MD @MayoClinic Thank you so much, Dr. Aminian.
Your mentorship has shaped both my career and character more than words can say.
I’ll carry what I learned from you into every step of what comes next.🙏

[Roham Foroumadi @RForoumadi]

As someone who once struggled with obesity and lost 70 lbs over the years, there were days I never thought I would outrun it, physically or emotionally.

But I did. And today, I did a full marathon.

This is just a reminder that:

WE CAN BEAT OBESITY.

#obesity #weightlossjourney

[Roham Foroumadi @RForoumadi]

@OMGhanemMD @MayoClinicSOM @MayoClinicSurg Congratulations, Dr. Ghanem! 👏
I have heard so many wonderful things about you! Truly excited for the opportunity to learn from you!

[Ali Aminian @Ali_Aminian_MD]

With routine care, half of patients with compensated MASH cirrhosis & obesity develop major adverse outcomes (MALO—such as liver failure, cancer, transplant, death) in 15 yrs.

🔥Bariatric surgery reduces that risk by 72%.
https://t.co/1vUWwCM9ht
#DDW2025 #EASL2025 #EASLCongress

[Ali Aminian @Ali_Aminian_MD]

Please consider joining us tomorrow for an exciting topic:

🔥Throw Away Your Surgical Staplers, It’s Time to Use Magnets!🔥

@SWexner @MRegueiroMD @ASMBS @ASCRS_1 @SAGES_Updates @AmCollSurgeons @DrdelaCruzMunoz

[Michael Albert, MD @MichaelAlbertMD]

1.27 million Americans have a BMI of 60 or greater.

To put that into perspective, that’s roughly 200–250 pounds of excess weight (based on the average height of a U.S. adult).

Tirzepatide: ~80 lbs weight loss → Final weight: ~300 lbs

Semaglutide: ~57 lbs weight loss → Final weight: ~325 lbs
@Ali_Aminian_MD @NeilFlochMD

[Dr. Spencer Nadolsky @DrNadolsky]

Being pro-medicine doesn’t mean you’re anti-lifestyle.

[The Lancet Diabetes & Endocrinology @TheLancetEndo]

New—Disproportionate increase in BMI of ≥60 kg/m2 in the USA https://t.co/LDyGfv98l4
#obesity #USA
#FREE to read

[Michael Albert, MD @MichaelAlbertMD]

The Rise of Extreme Obesity (BMI ≥60 kg/m²): A Public Health Crisis in the Making
- - -
🚨 New data from NHANES shows an alarming trend:

The prevalence of BMI ≥60 kg/m² has tripled over the past two decades — from 0.12% (2001–04) to 0.37% (2021–23).

These individuals face 2–3x higher rates of comorbidities, surgical complications, and mortality.

Healthcare systems are not prepared: standard equipment, imaging machines, and surgical facilities often cannot accommodate these patients.

Many are excluded from clinical trials, further marginalizing their access to treatments like GLP-1 receptor agonists.

Key Findings:
🔹 Normal weight (BMI 18.5–24.9) and overweight (BMI 25–29.9) populations are shrinking.
🔹 Severe and extreme obesity categories are growing rapidly.
🔹 BMI ≥60 kg/m² risk ratio (2021–23 vs 2001–04): 3.11 (95% CI 1.35–7.15).

Why It Matters:
🔸Extreme obesity is real, growing, and underrepresented.
🔸Many national health surveys label BMI ≥60 kg/m² as "biologically implausible," underestimating the crisis.
🔸If unaddressed, health disparities and clinical system failures will widen.

We urgently need:
✅ Dedicated research for extremely high BMI populations
✅ Specialized medical infrastructure
✅ Public health interventions tailored to this group
https://t.co/oOfsPWW9X9